¼¼°èÀÇ ÀǾàǰ ¼öŹ Æ÷Àå ½ÃÀå ±Ô¸ð Á¶»ç : Á¦Ç° À¯Çüº°, ÇüÅ À¯Çüº°, ¿ëµµ À¯Çüº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)
Global Pharmaceutical Contract Packaging Market Size Study, by Product Type, by Form Type, by Application Type and Regional Forecasts 2022-2032
»óǰÄÚµå : 1527275
¸®¼­Ä¡»ç : Bizwit Research & Consulting LLP
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 285 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 7,162,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,250 £Ü 9,043,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è ÀǾàǰ À§Å¹ Æ÷Àå ½ÃÀåÀº 2023³â¿¡ ¾à 61¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, ¿¹Ãø ±â°£ 2024-2032³â¿¡´Â 7.5% ÀÌ»óÀÇ °ß½ÇÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

ÀǾàǰ ¼öŹ Æ÷ÀåÀº ÀǾàǰ Æ÷Àå °øÁ¤À» Àü¹® Á¦3ÀÚ ±â¾÷¿¡ À§Å¹ÇÏ¿© ºí¸®½ºÅÍ ÆÐÅ·, º´ Æ÷Àå, ¶óº§¸µ, 2Â÷ Æ÷Àå µîÀÇ ¼­ºñ½º¸¦ Á¦°øÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ¿¡ µû¶ó Á¦¾àȸ»ç´Â ±ÔÁ¦±âÁØÀÇ Áؼö¸¦ È®º¸Çϸ鼭 ÀǾàǰ °³¹ßÀ̳ª ¸¶ÄÉÆÃ µîÀÇ ÇÙ½É ¾÷¹«¿¡ ÁýÁßÇÒ ¼ö ÀÖ½À´Ï´Ù. À§Å¹ Æ÷Àå¾÷ÀÚ´Â Æ÷Àå ±â¼ú, ǰÁú °ü¸® ¹× °ø±Þ¸Á °ü¸®¿¡ ´ëÇÑ Àü¹® Áö½ÄÀ» Á¦°øÇÏ¿© ºñ¿ë Àý°¨, È¿À²¼º Çâ»ó ¹× À¯Åë ÇÁ·Î¼¼½º Àü¹Ý¿¡ °ÉÃÄ Á¦Ç°ÀÇ ¾ÈÀü°ú ¹«°á¼ºÀ» º¸ÀåÇÕ´Ï´Ù.

½ÅÈï±¹ÀÇ Ç°Áú ¿ä°ÇÀÇ ¾ö°ÝÈ­¿Í ÀǾàǰ Æ÷ÀåÀÇ ¼öʾ÷ÀÚ¿¡ ´ëÇÑ ¾Æ¿ô¼Ò½Ì Áõ°¡°¡ ¿¹Ãø ±â°£ Áß ½ÃÀåÀÇ °ßÀοªÀÌ µÉ Àü¸ÁÀÔ´Ï´Ù. Á¦¾à ȸ»ç´Â Àüü »ý»ê ºñ¿ëÀ» ÁÙÀÌ°í ½ÃÀå Ãâ½Ã¸¦ °¡¼ÓÈ­Çϱâ À§ÇØ Æ÷Àå ÀÛ¾÷À» À§Å¹ Æ÷Àå ¾÷ü¿¡ ¾Æ¿ô¼Ò½ÌÇÕ´Ï´Ù. À̰ÍÀº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, »ç³»¿¡ ÆÐŰ¡ ´É·Â, Àü¹® Áö½Ä, ¿¹»êÀÇ Á¦¾àÀÌ ¾ø´Â °ÍÀÌ, ÀÌ ¾÷°èÀÇ ¼Ò±Ô¸ð Á¦¾àȸ»ç°¡ Á÷¸éÇÏ´Â ÁÖ¿äÇÑ ¹®Á¦ÀÔ´Ï´Ù. À§Å¹ Æ÷Àå ¼­ºñ½º Á¦°ø ¾÷ü´Â Àú·ÅÇÑ ºñ¿ëÀ¸·Î ¼­ºñ½º¸¦ Á¦°øÇÒ ¼ö ÀÖÀ¸¹Ç·Î ¼Ò±Ô¸ð ±â¾÷ÀÇ ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇÏ´Â È¿°úÀûÀÎ Á¢±Ù¹ýÀ¸·Î Àνĵǰí ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÚ¿ø°ú ¿¹»êÀÌ ºÎÁ·Çϱ⠶§¹®¿¡ ¸¹Àº ¼Ò±Ô¸ð Á¦¾à ȸ»ç´Â Æ÷Àå ¼öŹ ±â°ü(CPO) ¹× °³¹ß ¹× Á¦Á¶ ¼öŹ ±â°ü(CDMO)°ú »óÈ£ À¯ÀÍÇÑ °ü°è¸¦ ±¸ÃàÇϰí ÀÖ½À´Ï´Ù. °è¾à ¼­ºñ½º Á¦°ø¾÷ü´Â °í°´ÀÇ ±â´ë¿¡ ºÎÀÀÇÏ¿© °íµµ·Î Á¤±³ÇÑ Æ÷Àå Àåºñ¸¦ Á¦°øÇϱâ À§ÇØ ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼¼°è Á¦¾à »ê¾÷ÀÇ ¼ºÀåÀÌ ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Æ÷Àå ¾÷¹« ¾Æ¿ô¼Ò½Ì¿¡´Â °í±Þ ÆÐŰ¡ ±â¼ú¿¡ ´ëÇÑ ¾×¼¼½º, È¿À²¼º Çâ»ó, ÇÙ½É ºÐ¾ß¿¡ ÁýÁß, ¼÷·ÃµÈ ¸®¼Ò½º¿¡ ´ëÇÑ ¾×¼¼½º, º¸´Ù ºü¸£°í ¿ì¼öÇÑ ¼­ºñ½º µî ¿©·¯ °¡Áö ÀÌÁ¡ÀÌ Àֱ⠶§¹®¿¡ Á¦¾à ȸ»ç´Â CPO ¹× CDMO¿¡ ´ëÇÑ Æ÷Àå ¼­ºñ½ºÀÇ ¾Æ¿ô¼Ò½ÌÀ» ´Ã¸®°í ÀÖ½À´Ï´Ù.

¹Ì±¹ÀÇ Drug Supply Chain Security Act(DSCSA) ¹× EUÀÇ Falsified Medicines Derivative(FMD) µîÀÇ Á÷·ÄÈ­¸¦ ½Ç½ÃÇÔÀ¸·Î½á ÀǾàǰ Æ÷Àå¿¡ ¹ÙÄڵ尡 Àǹ«È­µÇ¾î ÀǾàǰ °ø±Þ¿¡ À־ ´ë·®ÀÇ µ¥ÀÌÅͰ¡ Àü¼ÛµÇ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÌÀ¯·Î Á¦Á¶ ±â¾÷Àº ÀÌ »õ·Î¿î ¹ý±Ô¿¡ ´ëÀÀÇϱâ À§ÇÑ ÀûÀýÇÑ ÀÎÇÁ¶ó¸¦ ±¸ÃàÇÒ Çʿ䰡 ÀÖ½À´Ï´Ù. Á÷·ÄÈ­ÀÇ ¼Ò°³´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±â¼ú Çõ½Å, Àα¸ Áõ°¡, °Ç°­ ÀǽÄ, ÷´Ü Á¦Á¶ ±â¼ú µµÀÔ, °øÁß º¸°Ç ½Ã½ºÅÛÀÇ ÁöÃâ Áõ°¡, Àü¿°º´ °¨¿°À» ¾ïÁ¦Çϱâ À§ÇÑ Á¤ºÎÀÇ »õ·Î¿î ±ÔÁ¦ µµÀÔ µîÀÌ ¼ºÀåÀÇ ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ¹ÙÀÌ¿ÀÁ¦Ç°À̳ª À¯ÀüÀÚ¡¤¼¼Æ÷Ä¡·á µîÀÇ »õ·Î¿î Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â Á¦¾àȸ»çÀÇ ÆÇ¸ÅÃËÁø¿¡ µµ¿òÀÌ µÇ°í ÀÖ¾î ÀÌ·¯ÇÑ Æ÷ÀåÁ¦Ç° ¼ö¿ä¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù.

ºÏ¹Ì´Â °è¾àÀ» ÅëÇØ È¿°úÀûÀÎ ÀǾàǰ Æ÷Àå ¼Ö·ç¼ÇÀÇ ¼¼°è ¼ö¿äÀÇ °ÅÀÇ 1/3À» »ý»êÇÔÀ¸·Î½á ÁÖ¿ä ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÕ´Ï´Ù. ¹Ì±¹¿¡¼­¸¸ »ý»êµÈ ÃÑ ¸ÅÃâÀº ºÏ¹Ì ÃÑ »ç¾÷ÀÇ ¾à 90%·Î ¹àÇôÁ³½À´Ï´Ù. ¹Ì±¹¿¡ º»»ç¸¦ µÐ CPO¿Í CDMO°¡ Á¦°øÇÏ´Â °íǰÁú ¼­ºñ½º´Â ÀÌ ³ª¶óÀÇ ÀǾàǰ Æ÷Àå À§Å¹ ¼­ºñ½º ¹× ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. »ý¹°ÇÐÀû ¿ä¹ý ¼ö¿ä, ¾ö°ÝÇÑ ÇÁ·ÎÅäÄÝ Áõ°¡, ³ëÀÎ Àα¸ Áõ°¡µµ ¼¼°è ÀǾàǰ À§Å¹ Æ÷Àå ½ÃÀå ±Ô¸ð¸¦ È®´ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡´Â ¼ö¸¹Àº ¼öŹ Æ÷Àå ¼­ºñ½º Á¦°ø¾÷ü°¡ Àֱ⠶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ±â¾÷µéÀº Á¦¾à ±â¾÷ Áõ°¡ÇÏ´Â ¿ä±¸¸¦ ÃæÁ·½Ã۱â À§ÇØ ½Ã¼³ È®Àå¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ Àεµ µî ½ÅÈï±¹À¸·ÎÀÇ ÀǾàǰ Á¦Á¶ ¾Æ¿ô¼Ò½ÌÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÀǾàǰ ¼öŹ Æ÷Àå ¼¼°è ½ÃÀå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼¼°èÀÇ ÀǾàǰ ¼öŹ Æ÷Àå ½ÃÀå Á¤ÀÇ¿Í Á¶»çÀÇ ÀüÁ¦Á¶°Ç

Á¦3Àå ÀǾàǰ ¼öŹ Æ÷Àå ¼¼°è ½ÃÀå ¿ªÇÐ

Á¦4Àå ¼¼°èÀÇ ÀǾàǰ ¼öŹ Æ÷Àå ½ÃÀå »ê¾÷ ºÐ¼®

Á¦5Àå ÀǾàǰ ¼öŹ Æ÷Àå ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Á¦Ç° À¯Çüº°-2022-2032

Á¦6Àå ÀǾàǰ ¼öŹ Æ÷Àå ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ÇüÅ À¯Çüº°-2022-2032

Á¦7Àå ÀǾàǰ ¼öŹ Æ÷Àå ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ¿ëµµ À¯Çüº°-2022-2032

Á¦8Àå ÀǾàǰ ¼öŹ Æ÷Àå ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø :Áö¿ªº°-2022-2032

Á¦9Àå °æÀï Á¤º¸

Á¦10Àå Á¶»ç °úÁ¤

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Pharmaceutical Contract Packaging Market is valued approximately at USD 6.1 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.5% over the forecast period 2024-2032. Pharmaceutical contract packaging involves outsourcing the packaging process of pharmaceutical products to specialized third-party companies, which provide services such as blister packing, bottling, labelling, and secondary packaging. This allows pharmaceutical companies to focus on core activities like drug development and marketing while ensuring compliance with regulatory standards. Contract packagers offer expertise in packaging technology, quality control, and supply chain management, helping to reduce costs, enhance efficiency, and ensure product safety and integrity throughout the distribution process.

Increasing stringent quality requirements and outsourcing of pharmaceutical packaging to contract packagers in emerging countries are expected to drive the market over the forecast period. Pharmaceutical companies are outsourcing the packaging activities to contract packagers to reduce the overall cost of production and speed to market. This is anticipated to contribute to the growth of the market over the forecast period. In addition, lack of in-house packaging capabilities, expertise, and budget constraints are the major issues faced by small pharmaceutical companies in the industry. Contract packaging service providers are recognized as an effective approach to curb such issues of the small companies owing to the low-cost service offering. However, lack of resources and budgets has prompted many small pharmaceutical companies to establish mutually beneficial relationships with Contract Packaging Organizations (CPOs) and Contract Development and Manufacturing Organizations (CDMOs). Contract service providers are making significant attempts to meet their client's expectations and provide highly sophisticated packaging facilities. Moreover, the growing pharmaceutical industry across the globe is anticipated to drive the market. As outsourcing of packaging activities offers several benefits such as access to advanced packaging technologies, increased efficiency, focus on core areas, access to skilled resources, and faster and better services, pharmaceutical companies are increasingly outsourcing the wrapping services to the CPOs and CDMOs.

The implementation of serialization including the Drug Supply Chain Security Act (DSCSA) in the U.S. and the EU Falsified Medicines Derivative (FMD) has mandated the barcodes on pharmaceutical packaging and the transfer of large volumes of data in the supply of medicines. This has made manufacturing companies develop appropriate infrastructure to comply with this new legislation. The introduction of serialization is expected to drive the market over the forecast period. Technological innovations, population increase, health awareness, the implementation of advanced manufacturing techniques, higher spending in public health systems, and the government implementation of new regulations to control the transmission of contagious diseases are all contributing factors to the growth. Furthermore, the growing demand for bio-products and new treatments such as gene and cell therapies are helpful to promote the pharmaceutical companies thereby increasing the demand for such packaging products.

North America accounts for the leading market share by generating almost one-third of the global demand for effective pharmaceutical packaging solutions through contracts. The total revenue generated by the United States alone was figured out to be around 90% of the total business in North America. Quality services offered by the CPOs and CDMOs based in the United States propel the demand for pharmaceutical contract packaging services and solutions in the country. The demand for biological therapies, increase in strict protocols, and rise in the geriatric population could also broaden the global pharma contract packaging market size. However, Asia Pacific is expected to witness the fastest growth over the forecast period due to the presence of a large number of contract packaging service providers in the region. These players are focusing on expanding their facilities to satisfy the growing needs of pharmaceuticals companies. In addition, increasing the outsourcing of pharmaceutical manufacturing to emerging countries such as India is further driving the growth of the market in the region.

Major market players included in this report are:

The detailed segments and sub-segment of the market are explained below:

By Product Type:

By Form Type:

By Application Type:

By Region:

Years considered for the study are as follows:

Key Takeaways:

Table of Contents

Chapter 1. Global Pharmaceutical Contract Packaging Market Executive Summary

Chapter 2. Global Pharmaceutical Contract Packaging Market Definition and Research Assumptions

Chapter 3. Global Pharmaceutical Contract Packaging Market Dynamics

Chapter 4. Global Pharmaceutical Contract Packaging Market Industry Analysis

Chapter 5. Global Pharmaceutical Contract Packaging Market Size & Forecasts by Product Type 2022-2032

Chapter 6. Global Pharmaceutical Contract Packaging Market Size & Forecasts by Form Type 2022-2032

Chapter 7. Global Pharmaceutical Contract Packaging Market Size & Forecasts by Application Type 2022-2032

Chapter 8. Global Pharmaceutical Contract Packaging Market Size & Forecasts by Region 2022-2032

Chapter 9. Competitive Intelligence

Chapter 10. Research Process

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â